<i>Conclusions:</i> The NMA indicates efficacy of ixekizumab and brodalumab (IL-17 inhibitors), guselkumab (IL-23 inhibitor), and spesolimab (IL-36 inhibitor) in managing palmoplantar pustulosis. Here, IL17A is linked to palmoplantar pustulosis.